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SAFETY AND SKIN DELAYED-TYPE HYPERSENSITIVITY RESPONSE IN VERVET MONKEYS 
IMMUNIZED WITH Leishmania donovani SONICATE ANTIGEN DELIVERED WITH ADJUVANTS
Joshua M. MUTISO(1,3), John C. MACHARIA(1), Evans TARACHA(1), Kellern WAFULA(2), Hitler RIKOI(1) & Michael M. GICHERU(3)
SUMMARY
In this study, we report on the safety and skin delayed-type hypersensitivity (DTH), responses of the Leishmania donovani whole 
cell sonicate antigen delivered in conjunction with alum-BCG (AlBCG), Montanide ISA 720 (MISA) or Monophosphoryl lipid A 
(MPLA) in groups of vervet monkeys. Following three intradermal injections of the inoculums on days 0, 28 and 42, safety and DTH 
responses were assessed. Preliminary tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) levels were also measured 
and these were compared with DTH. Only those animals immunized with alum-BCG reacted adversely to the inoculum by producing 
ulcerative erythematous skin indurations. Non-parametric analysis of variance followed by a post-test showed significantly higher DTH 
responses in the MISA+Ag group compared with other immunized groups (p < 0.001). The MPLA+Ag group indicated significantly 
lower DTH responses to the sonicate antigen compared with the AlBCG+Ag group. There was a significant correlation between the 
DTH and cytokine responses (p < 0.0001). Based on this study we conclude that Leishmania donovani sonicate antigen containing 
MISA 720 is safe and is associated with a strong DTH reaction following immunization.
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INTRODUCTION
Visceral leishmaniasis (VL) or kala-azar is the most dreaded and 
devastating amongst the various forms of leishmaniasis (GARG & 
DUBE, 2006). The disease is a major cause of morbidity and mortality 
in East Africa and the Indian subcontinent. Coinfection with HIV 
enhances the risk of the disease (NGURE et al., 2009). The only 
control measures currently available in East Africa are case detection 
and treatment with antimonial drugs, which are expensive, toxic, 
not always available and cannot be self-administered. Vector and 
reservoir control is difficult due to the elusive nature of the vector and 
the diversity of the animal reservoir. Cases of self-cure in cutaneous 
leishmaniasis, accompanied by solid immunity to reinfection, make 
vaccine development a feasible control method (MUTISO et al., 
2010a). Cellular or Th1 immune response is important for the cure of 
leishmaniasis. This involves the activation of infected macrophages 
by sensitized T cells to produce parasite lethal nitric oxide. The use 
of adjuvants in effective Leishmania vaccine development cannot be 
avoided. The availability of many potential adjuvants has prompted 
the need for identifying rational standards for the selection of adjuvant 
formulations based on safety and sound immunological principles 
for human vaccines (ALVING, 2002). Three effective adjuvants that 
have shown promising results in Leishmania vaccine studies have 
been identified in a recent review (MUTISO et al., 2010a). These 
adjuvants include: Montanide ISA 720 (MUTISO et al., 2010b), alum 
formulated with BCG (MISRA et al., 2001; KAMIL et al., 2003) and 
Monophosphoryl lipid A (SKEIKY et al., 2002; COLER & REED, 
2005; COLER et al., 2007). Despite a lot of vaccination research using 
these adjuvants, it is not readily clear which of them is more superior 
in terms of safety and immunogenicity and hence which of them is 
most appropriate for use in the development of Leishmania vaccines. 
Skin delayed-type hypersensitivity (DTH) response has been used 
as an indicator of the immunogenicity in an immunization antigen 
measured by the presence of a specific cellular type of immune reaction 
(GICHERU et al., 2001; RITTER & KORNER, 2002; MASINA et al., 
2003). The present report describes a study undertaken to evaluate the 
safety and DTH response of Leishmania donovani sonicate antigen 
delivered together with each of the three selected adjuvants in the vervet 
monkey model with visceral leishmaniasis. The study also measured and 
compared preliminary TNF-α and IFN-γ levels with the DTH response.
MATERIALS AND METHODS
Leishmania parasites: The Leishmania donovani strain NLB-065 
originated from the spleen of an infected patient in the Baringo district of 
Kenya and was maintained by intracardiac hamster-to-hamster passage 
at the Institute of Primate Research. A hamster splenic biopsy was 
cultured in Schneider’s drosophila insect medium and was supplemented 
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with 20% fetal bovine serum and 100 μg/mL of gentamicin at 25 °C till 
the stationary phase. Stationary phase promastigotes were harvested at 
2500 rpm (Servoll 6000D) for 15 min at 4 °C. The pellets were washed 
three times in sterile phosphate buffered saline (PBS) by centrifugation. 
These parasites were used for antigen preparation, immunization and 
DTH assessment.
Adjuvants and vaccine preparation: Monophosphoryl lipid A 
(InvivoGen), Montanide ISA 720 V (Seppic), alum (Rehydragel HPA; 
Reheis, Berkeley Heights, NJ) and BCG (Serum Institute of India, 
Hadapsar, India) were used as adjuvants in this study. The immunization 
antigen was prepared from Leishmania donovani promastigotes. 
Stationary phase promastigotes were harvested as previously described, 
counted and resuspended in 3 mL PBS at a concentration of 8 x 108 
promastigotes. These promastigotes were frozen - thawed three times in 
liquid nitrogen and sonicated at 18 kHz for five periods of 45 seconds each 
on ice, separated by one minute intervals. Each dose of the immunization 
and DTH assessment antigen was prepared from 1 × 107 promastigotes 
equivalent to 100 μg of Leishmania donovani sonicate antigen.
Vervet monkeys: Both young and adult vervet monkeys of both sexes 
were caught in the wild and quarantined for 120 days at the Institute 
of Primate Research, Karen, Nairobi, Kenya. During the quarantine 
period, the monkeys were monitored for Mycobacterium tuberculosis 
infection and gastrointestinal and parasitic infections. The animals were 
tested for antileishmanial antibodies against both Leishmania donovani 
and L. major antigen by ELISA and monkeys with no antibody titer 
were selected for the study. These animals were housed individually 
in squeeze-back cages and fed a commercial non-human primate meal, 
supplemented weekly with fruits and vegetables. Water was provided ad 
libitum. Institutional Animal Care and Use and Institutional Scientific 
resources and Evaluation Committee guidelines were strictly followed.
Experimental protocol: Leishmania donovani antibody-free adult 
vervet monkeys with a mean body weight of 3.4 kg were selected and 
divided into five groups of three monkeys each as follows: Group 1, 
alum precipitated sonicate plus BCG (AlBCG+Ag); Group 2, sonicate 
plus monophosphoryl lipid A (MPLA+Ag); Group 3, sonicate plus 
montanide ISA 720 (MISA+Ag); Group 4, sonicate (Ag) alone and Group 
5 non-vaccinated control (naïve control). The experimental groups were 
vaccinated three times intradermally on days 0, 28, and 42. Between days 
0 and 60 vaccinated animals were monitored for safety parameters. The 
skin delayed-type hypersensitivity responses were assessed on day 63 
following 72 hours of intradermal antigen inoculation. The DTH results 
were compared with preliminary TNF-α and IFN-γ levels (measured on 
day 63 following initial vaccination) to ascertain the usefulness of using 
DTH as a predictive marker of Th1 immune responses in immunized 
subjects.
Assessment of safety: The animals were observed for any induration 
and erythema at the sites of vaccine injection. Examination of the regional 
lymphadenopathy was also carried out. Body temperature and weight 
changes were also monitored.
Assessment of skin delayed-type hypersensitivity (DTH): Three 
weeks after the third vaccination, animals were assessed for DTH 
responses by intradermal inoculation with 100 μg of L. donovani antigen, 
equivalent to sonicated Leishmania donovani promastigotes in 100 μL 
of PBS. Seventy two hours later, skin indurations at the inoculation sites 
were measured using a metric caliper as described (GICHERU et al., 
2001). A mean induration diameter >5 mm was considered to be positive.
Quantification of cytokines: Tumor necrosis factor alpha and 
IFN-γ were measured in cell-culture supernatants. Peripheral blood 
mononuclear cells (PBMCs) were isolated from the whole blood by 
density gradient centrifugation as described (OLOBO et al., 1990). 
Purified cells were adjusted to 3 x 106/mL in a complete RPMI 1640 
medium and stimulated with Leishmania donovani antigen as previously 
described (GICHERU et al., 1995). Cultures supernatants were collected 
from triplicate wells after 72 hours of stimulation and the concentration 
of TNF-α and IFN-γ in the supernatant was determined by enzyme linked 
immunosorbent assay (ELISA). Polystyrene flat bottomed micro-ELISA 
plates (Dynatech Laboratories, Sussex, UK) were briefly coated overnight 
with 50 μL of 2 μg/mL of capture monoclonal antibodies (Becton 
Dickinson and MabTech, Sweden) diluted in bicarbonate buffer, pH 9.6. 
Excess coating buffer was removed, and non-specific binding sites were 
blocked in 3% bovine serum albumin (Sigma) in PBS for one hour at 
37 °C. The plates were washed four times with 0.005% Tween 20 in PBS, 
and 50 μL of culture supernatant was dispensed to the appropriate wells. 
Human TNF-α (Becton Dickinson) and IFN-γ diluted (1 to 600 U/mL) 
in 1% bovine serum albumin in PBS-Tween were used as standards. 
The plates were incubated at 37 °C for one hour and washed four times 
before the addition of biotinylated secondary monoclonal antibodies 
(50 μL of 1/2000 dilution) followed by incubation at 37 °C for one hour. 
The plates were washed four times as before, 50 μL of 1/300-diluted 
alkaline phosphate-conjugated streptavidin was added, and the mixtures 
were incubated for one hour as described above. The plates were washed 
ten times in PBS-Tween, and 50 μL of nitrophenyl phosphate substrate 
(1 mg/mL) in diethanolamine buffer was added. The plate was incubated 
at 37 °C in the dark for 30 minutes, and absorbance was read at 405 nm. 
Statistical analysis: Non-parametric one-way analysis of variance 
(ANOVA) was used to compare the means of groups. The Tukey-Kramer 
test was used for inter-group statistical analysis. Differences were 
considered significant where p < 0.05. Spearman rank correlation was 
used for correlation analysis. 
RESULTS
Local reaction to Leishmania donovani sonicate antigen-adjuvant 
immunization: All animals in the AlBCG+Ag group showed indurations 
at the sites of vaccination. These indurations, measured seven days 
following immunizations, lasted between 34 and 41 days before complete 
resolution. These indurations were ulcerative and associated with 
erythema. Lymph node swellings were also observed in the AlBCG+Ag 
group and these resolved with the disappearance of indurations. Animals 
in other groups did not show any lymphadenopathy or local skin reaction 
to the immunizations. There were no systemic side-effects such as fever 
or weight loss in any of the animal groups following immunization. 
Delayed-type hypersensitivity response: All immunized monkeys 
developed DTH response to Leishmania donovani antigen as measured 
on day 21 after the second immunization booster. Post-test analysis 
indicated a significantly higher DTH reaction in the MISA+Ag group 
compared with each of the other groups (p < 0.001). The AlBCG+Ag 
group showed a significantly higher DTH response to the sonicate antigen 
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compared with the MPLA+Ag and Ag alone groups as well as the naïve 
control group (p < 0.001). It was interesting to note that there was no 
difference in DTH responses between the MPLA+Ag and the Ag alone 
groups (p > 0.05). The naïve control animals did not exhibit a positive 
DTH response as shown in Figure 1.
Th1 cytokine responses: Both AlBCG+Ag and MISA+Ag 
vaccinated groups induced comparable TNF-α cytokine levels (p > 
0.05) which were significantly higher (p < 0.05) than the levels produced 
by the MPLA+Ag group. Although the MPLA+Ag immunized group 
induced significantly higher (p < 0.05) TNF-α levels than the control 
group, it was interesting to note that the cytokine levels induced in both 
Ag and MPLA+Ag groups were comparable (p > 0.05; Fig. 2). This 
trend of TNF-α production was similar to the IFN-γ production except 
that, MPLA+Ag induced significantly higher levels of IFN-γ compared 
with the Ag group (data not shown).
Relationship between DTH and Th1 cytokine responses: 
Spearman rank correlation analysis indicated a significant correlation 
between DTH responses and corresponding TNF-α values (r = 0.9374; 
p < 0.0001). A positive and significant correlation was also established 
between DTH and IFN-γ responses (r = 0.9410; p < 0.0001; Fig. 3).
DISCUSSION
Visceral leishmaniasis is a major health problem in East Africa where 
it is associated with frequent epidemics that claim hundreds of lives, 
especially in the remote areas where medical care facilities are limited. 
Available drugs are very expensive, and highly toxic. The development 
of a safe vaccine may provide an immunological control strategy. There 
is no available vaccine for the control of leishmaniasis to date (MUTISO 
et al., 2010b). It is apparent that an effective Leishmania vaccine will only 
be achieved by careful selection of both an appropriate adjuvant as well 
as an antigen (MUTISO et al., 2010a). Hundreds of different adjuvants 
exist, and these need to be selected on the basis of their safety and sound 
immunological principles. Promising adjuvants include Montanide ISA 
720 MUTISO et al., 2010b), alum/BCG (MISRA et al., 2001; KAMIL 
et al., 2003) and Monophosphoryl lipid A (COLER et al., 2007). These 
adjuvants have been associated with Th1 cytokine as well as humoral 
immune responses. It is not yet clear which of these adjuvants would 
be superior in inducing a cellular immune response required for the 
control of leishmaniasis. Positive DTH response is a marker of a type 
1 immune response and has been used to assess the immunogenicity of 
candidate vaccine antigens against leishmaniasis (MISRA et al., 2001; 
GICHERU et al., 2001; MASINA et al., 2003). This study set out to 
identify the most important adjuvant for the development of leishmania 
Fig. 1 - Skin delayed-type hypersensitivity (DTH) responses in vervet monkeys following 
immunizations. Animals were immunized at three different points in time with sonicate 
antigen (Ag) alone; sonicate antigen plus alum plus BCG (AlBCG+Ag); sonicate antigen plus 
monophosphoryl lipid A (MPLA+Ag) or sonicate plus montanide ISA 720 V (MISA+Ag) 
and the DTH determined on day 63 following initial immunization. Data shown indicates the 
mean DTH ± SD in each immunization group. A DTH value < 5 mm was considered negative.
Fig. 2 - Level of TNF-α response to Leishmania donovani antigen in vervet monkeys 
vaccinated at three different points in time with sonicate antigen (Ag) alone; or in conjunction 
with alum plus BCG (AlBCG+Ag); monophosphoryl lipid A (MPLA+Ag) or montanide 
ISA 720 V (MISA+Ag). The values for the antigen-adjuvant vaccinated animals on day 
63 following initial vaccination were comparable with AlBCG+Ag and MISA+Ag and 
significantly higher (p < 0.05) than with the MPLA+Ag group.
Fig. 3 - Relationship between delayed-type hypersensitivity (DTH) skin and IFN-γ. Animals 
were immunized at three different points in time with sonicate antigen (Ag) alone; or in 
conjunction with alum plus BCG (AlBCG+Ag); monophosphoryl lipid A (MPLA+Ag) or 
montanide ISA 720 V (MISA+Ag) and the DTH and IFN-γ determined on day 63 following 
initial immunization and a correlation analysis between DTH and IFN-γ was carried out. A 
DTH value of 5 mm and above was considered positive. Data shown indicates a positive and 
significant correlation between DTH and IFN-γ responses. 
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vaccines. Parameters assessed included safety and immunogenicity 
based on positive DTH and Th1 cytokine (TNF-α and IFN-γ). A recent 
study carried out in our laboratory indicated montanide ISA 720 as a 
better adjuvant than BCG for leishmania vaccines in mice (MUTISO et 
al., 2010b). The study recommended confirmation of these results in a 
non-human primate model of the disease.
The results of our present study show that based on two clinical 
parameters including fever and changes in body weight, the immunization 
protocols are safe. Following initial immunization, daily observation of 
immunized animals was carried out and we did not observe any local or 
systemic side effects in any of the animals immunized with MPLA+Ag 
or MISA+Ag. The safety of MISA has been reported elsewhere including 
in vaccination studies carried out in our laboratory (TOLEDO et al., 
2001; MASINA et al., 2003; OLIVEIRA et al., 2005). Our safety 
report on MISA as an adjuvant for Leishmania vaccine differs from 
other studies that have associated this adjuvant with adverse reactions 
including swelling and erythema at the injection site observed within 
a few days following vaccination (PIERCE et al., 2010). Other studies 
have reported occasional unacceptable local reactogenicity in vaccines 
containing montanides (WU et al., 2008). It is likely that adverse 
reactions observed following immunizations with vaccines containing 
MISA may be a result of the immunizing antigen. Monophosphoryl 
lipid A has also been found to be safe in a vaccine study performed on 
healthy human toddlers (VERNACCHIO et al., 2002). Earlier studies 
had also indicated the safety and effectiveness of MPLA in Leishmania 
vaccine studies (REED et al., 2003). The additional safety evaluation of 
MPLA as an adjuvant for clinical trials had earlier been performed on 
dogs, rabbits and rats (BALDRICK et al., 2002). However, as a matter 
of serious concern, the study has established that, based on adverse 
local skin reaction, an immunization containing BCG is not safe as it is 
associated with erythematous ulcerative skin nodules or indurations. This 
confirms the results observed in our earlier study on mice (MUTISO et 
al., 2010b) where vaccination with BCG was associated with adverse 
reaction. Other studies involving the use of the monkey system have 
also associated BCG with severe reactions (MISRA et al., 2001). 
Lymphadenopathy was also an undesirable feature in the use of BCG 
as an adjuvant in this study. Delayed-type hypersensitivity response to 
the Leishmania donovani antigen was prominent in the animal group 
immunized with sonicate plus MISA, an indication that this adjuvant may 
be important for the development of a safe and effective vaccine against 
visceral leishmaniasis. Remarkable levels of TNF-α and IFN-γ induced 
by groups vaccinated with antigen containing Alum-BCG and MISA 
indicates the superiority of these adjuvants in the selective induction of 
Th1 immune responses. Alum-BCG has been indicated to induce strong 
Th1 immune responses in Leishmania vaccine studies (MISRA et al., 
2001; KAMIL et al., 2003). In malaria, HIV and cancer vaccine studies, 
MISA 720 has been indicated to induce high Th1 immune responses 
important for the control of these diseases (KENNEY & ELDELMAN, 
2003). This adjuvant has also been shown to induce strong Th1 cytokine 
in Leishmania vaccination studies (MASINA et al., 2003; MUTISO et 
al., 2010b). The strong correlation between DTH and both TNF-α and 
IFN-γ responses in the present study indicates the importance of the DTH 
response as an early marker of the outcome of a vaccination study. It may 
be possible that, very expensive experimental vaccination studies may 
be designed to predict field trial outcome by preliminary determination 
of DTH responses. However, optimization studies need to be carried out 
to validate this observation. Although immunization with AlBCG+Ag 
and MISA 720 induced comparable and significantly higher DTH and 
Th1 cytokine responses compared with the MPLA+Ag immunization, 
the association of BCG with adverse skin reaction may preclude it from 
future evaluation for possible use in the development of a safe vaccine 
in humans. Monophosphoryl lipid A has been indicated as an adjuvant 
with desirable results in vaccination studies against murine leishmaniasis 
(COLER et al., 2007). In the present study, the failure of the MPLA+Ag 
immunized group to induce a higher DTH reaction than the Ag alone 
group may be a factor in the MPLA formulation. COLER et al. (2007) 
used the oil based MPL-ES (MPL-A in stable emulsion) while our current 
study used MPL-A based on aqueous formulation. Furthermore the 
MPLA used in this study, a natural product, is a heterogeneous mixture, 
which may affect its effectiveness (COLER et al., 2009).
We conclude that, the intradermally injected Leishmania donovani 
sonicate antigen plus montanide ISA 720 was safe and that the rate of 
skin delayed-type hypersensitivity conversion is higher than that induced 
by AlBCG+Ag or MPLA+Ag. In addition, although both MISA+Ag and 
AlBCG+Ag induce desirable TNF-α and IFN-γ responses, the association 
of AlBCG with unacceptable adverse reaction leaves montanide ISA 720 
V as a potentially superior adjuvant for candidate vaccine for visceral 
leishmaniasis. However, further studies are necessary to compare the 
immunogenicity between montanide ISA 720 and monophosphoryl lipid 
A formulated in a stable emulsion. 
RESUMO
Segurança e reação de hipersensibilidade tardia na pele de 
macacos vervet imunizados com antígeno sonicado de Leishmania 
donovani junto com adjuvantes
Neste estudo reportamos segurança e resposta de hipersensibilidade 
tardia (DTH) do antígeno sonicado de células totais de Leishmania 
donovani introduzidos juntamente com alume-BCG (AIBCG) Montanide 
ISA 720 (MISA) ou lípide A monofosforilado (MPLA) em grupos de 
macacos vervet. Depois de três injeções intradérmicas do inóculo nos dias 
0, 28 e 42 segurança e resposta DTH foram avaliados. Preliminarmente 
níveis de fator de necrose tumoral alfa (TNF-α) e interferon gama 
(IFN-γ) foram também medidos e comparados com o DTH. Somente 
os animais imunizados com alume-BCG reagiram de maneira diversa 
ao inóculo produzindo indurações ulceradas e eritematosas na pele. 
Análise não paramétrica de variação seguida por um teste posterior 
mostraram resposta significantemente mais alta do DTH no grupo MISA 
+ Ag quando comparado com outros grupos imunizados (p < 0.001). 
O grupo MPLA + Ag demonstrou resposta DTH significantemente 
menor do antígeno sonicado comparado com o grupo AIBCG + Ag. 
Houve correlação significante entre o DTH e a resposta às citocinas (p 
< 0.0001). Baseados neste estudo concluímos que o antígeno sonicado 
de Leishmania donovani contendo MISA 720 é seguro e está associado 
com forte reação DTH após imunização.
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